---
layout: default
title: Tremelimumab
parent: Model Prediction Only (L5)
nav_order: 930
evidence_level: L5
indication_count: 10
---

# Tremelimumab
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Tremelimumab: From Oncology (Anti-CTLA-4 Immunotherapy) to Diabetic Cataract

## One-Sentence Summary

Tremelimumab is an anti-CTLA-4 monoclonal antibody (T-cell checkpoint blockade) used in oncology.
The TxGNN model predicts it may be effective for **diabetic cataract**, but there are currently **0 clinical trials** and **0 publications** supporting this direction.
This is a model-only prediction, and the available evidence points to a possible safety concern rather than a benefit.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not listed in the available licence data (anti-CTLA-4 oncology drug) |
| Predicted New Indication | Diabetic cataract |
| TxGNN Prediction Score | 98.49% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 1 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the input. Based on known information, tremelimumab is a CTLA-4 checkpoint inhibitor that releases the brake on T-cell activation, so its action is immunological.

The predicted indication is a lens condition driven by hyperglycaemia, the polyol pathway and oxidative stress. No established CTLA-4 pathway role in cataract formation was identified. The high score (98.49%) most likely reflects graph-neighbourhood similarity among many cataract nodes in the knowledge graph, not a biological rationale.

All 10 top predictions are cataract or diabetic eye conditions with near-identical scores (98.2% to 98.5%): diabetic cataract, tetanic cataract, immature cataract, type 2 diabetes-associated cataract, mature cataract, craniostenosis cataract, nuclear senile cataract, cortical cataract, senile cataract, and diabetic retinopathy. This pattern suggests a graph artefact rather than independent signals. Several are also staging descriptors of lens opacity, likely redundant ontology nodes.

The direction of risk is also unfavourable. Checkpoint inhibitors are associated with immune-related adverse events, including ocular inflammation (e.g., uveitis) and immune-mediated diabetes. For diabetic retinopathy, established anti-VEGF therapies make an unproven systemic immunotherapy an unlikely candidate.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

| DIN | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| 2541009 | IMJUDO | Not specified | Not specified in the available data |

---

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Immunotherapy (anti-CTLA-4 checkpoint inhibitor), not a conventional cytotoxic |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Immune-related adverse events, particularly ocular inflammation and glycaemic status (immune-mediated diabetes) |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

- **Class-level concerns relevant to this prediction**: Checkpoint inhibitors can cause ocular immune-related adverse events (e.g., uveitis) and can induce autoimmune diabetes. For a diabetic eye indication, these are potential safety signals rather than therapeutic rationale.

Please refer to the package insert for full warnings, contraindications and drug interaction information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is model-only (L5), with no trials or literature and no plausible mechanistic link between CTLA-4 blockade and lens opacification. The known ocular and diabetes-related immune adverse events make the risk-benefit direction unfavourable.

**To proceed, the following is needed:**
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data (e.g., from DrugBank) to allow a mechanistic-link analysis
- The approved indication text for DIN 2541009, to confirm the original indication
- Any preclinical or clinical evidence linking CTLA-4 inhibition to lens or diabetic eye disease
- Route-of-administration compatibility assessment, which is still pending
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

